Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas

This publication has 33 references indexed in Scilit:

• Current Perspectives on HER2 Testing: A Review of National Testing Guidelines
  Laboratory Investigation, 2003
• Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup
  European Journal Of Cancer, 2002
• Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
  Journal of Clinical Oncology, 2002
• HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization
  Laboratory Investigation, 2001
• c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients
  International Journal of Cancer, 2000
• C-erbB-2 immunostaining: problems with interpretation.
  Journal of Clinical Pathology, 1994
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987
• Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene
  Science, 1985
• Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
  Cell, 1985
• Prognostic factors in osteosarcoma
  International Journal of Radiation Oncology*Biology*Physics, 1980